| Object:To investigate and compare the clinical efficacy and safety of regimens containing raltitrexed or capecitabine separately combined with bevacizumab in the treatment of advanced colorectal cancer.Methods:Data of patients with advanced colorectal cancer admitted to the Department of Oncology,the First Hospital of China Medical University were retrospected collected.Baseline characteristics,therapeutic evaluation results,adverse events were collected.SPSS 26.0 software was used to compare the baseline characteristics,survival outcomes and adverse events.Forestplot and survivorship curves were drawn by R 4.2.2 software.Pubmed,Embase,Cochrane and CNKI databases were searched for clinical trials of bevacizumab combined with raltitrexed-based or capecitabine-based chemotherapy.Meta-analysis were performed using R 4.2.2 software.Results:Clinical retrospective studies showed that there was no significant difference in ORR,DCR,PFS and OS.There was no significant difference in PFS and OS among baseline subgroups.Diarrhea and adverse heart diseases were higher in the capecitabine group than in the raltitrexed group.The incidence of elevated ALT and AST was higher in the raltitrexed group.40 articles were included in the meta-analysis,including 9 in the raltitrexed group and 34 in the capecitabine group.4065 patients were included.Neutropenia,fatigue,nausea,vomiting,thrombocytopenia,anemia and aminotransferase elevation were significantly higher in the raltitrexed group.The incidence of diarrhea in capecitabine group was significantly higher than that in raltitrexed group.Conclusion:Bevacizumab combined with raltitrexed or capecitabine in the treatment of advanced colorectal cancer has good efficacy and tolerable toxicity.Comparison studies suggest that the two regimens can achieve similar clinical efficacy and survival benefits,and there exists some difference in the occurrence of adverse events. |
PDF Full Text Request